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Significant Factors Influencing Kidney Graft Survival
J. J. van Rood, G. G. Persijn, L. C. Paul, B. Cohen, Q. Lansbergen, E. Goulmy,
F. H. J. Claas, W. Baldwin, and L. A. van Es
MANY factors influence the outcome ofa graft. This explains in part why it
took so long to come to some degree of agree-
ment on which factors determine graft
survival and their relative importance. As far
as the HLA-A and Β antigens are concerned,
there is now more or less a general agreement
that they are of importance, although there is
still disagreement on the question how much
difference HLA-A and Β matching can make
for graft survival. Some groups claim that
they can find a 40% difference between unre-
lated HLA-A and Β identical and HLA
mismatched grafts, while others find only a
difference of 10% or 15%.'·2
The influence of HLA matching not on
graft but on patient survival and the relation
between the match and immunosuppression is
still under study. In a collaborative analysis
between Eurotransplant and the European
Dialysis and Transplantation Association, a
clear-cut and quite significant influence of
HLA-A and Β matching on patient survival
was found.3 It is logical to assume that this is
due to the large amount of immunosuppres-
sion that must be given if the donor and
recipient are severely mismatched for the
HLA-A and Β antigens. That this might
indeed be true was shown by the clear-cut
correlation found between the number of
HLA-A and Β mismatches and the number of
rejection crisis treatments given.1
As far as pretransplant blood transfusion is
concerned, there is general agreement that
blood transfusions should be given, but more
study is needed to determine whether the
transfusion should be given pre- or pertrans-
plantation and the optimal number of transfu-
sions needed.4 As far as HLA-DR is
concerned, the only real agreement is that
more data are needed. The majority of the
published studies show a clear-cut effect of
HLA-DR matching, but the data collected
during the Eighth Histocompatibility Work-
shop were not convincing.5 Our data still
indicate a significant influence of DR match-
ing: the DR-identical grafts are doing much
better than those that are mismatched for 1 or
2 DR antigens.6
Next of course comes the question, whether
if one matches for HLA-DR one can "forget"
about HLA-A and Β matching. Our graft
survival data indicate that the effect of
HLA-DR matching is potentiated by HLA-A
and Β matching. In the HLA-DR-identical
group, graft survival is near 90% 1 year post-
transplant if donor and recipient are also
HLA-A and Β matched or mismatched for
only 1 antigen. On the other hand, HLA-DR
matching and blood transfusions do not
potentiate each other, or to a far lesser extent.
In other words, one can give either pretrans-
plant blood transfusions or one can select an
HLA-DR-identical donor to obtain almost
optimal results. Findings in the rhesus
monkey model are in agreement with the
human data.7 However, some of the kidney
grafts that were HLA-A and Β matched and/
or HLA-DR matched were rejected in the
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first 2 months after transplantation. This
might indicate that factors outside HLA
influence graft survival as well. This problem
was systematically studied by Paul et al.8 The
protocol they used is extremely simple. Before
transplantation, a biopsy of the donor kidney
is taken, snap frozen, and at different inter-
vals after transplantation, and of course if
graft rejection occurs, sections of this biopsy
are incubated with the serum of the patient,
washed, and then stained with FITC-labeled
antiimmunoglobulin. In this way antibodies
could be demonstrated in the serum of about
half of the patients who had rejected their
kidney allograft within 2 months after trans-
plantation. These antibodies only bind to the
endothelium of the peritubular capillaries. It
is tempting to speculate that the occurrence of
such antibodies could for instance lead to
platelet aggregation, and this to an irreversible
vascular rejection. It could also be proven that
the same antigen that is present on the endo-
thelium is also present on monocytes. In other
words, the endothelium and the monocytes
share alloantigens that can be recognized on
the endothelium by immunofluorescence and
on the monocytes by complement-dependent
cytotoxicity.9 These endothelium-monocyte
(EM) antibodies are formed especially in
kidney graft recipients that are HLA-DRw6
positive. Although the data are significant,
they should be interpreted with caution
because the number of observations is still
quite small, and secondly because the recogni-
tion of HLA-DRw6 is still quite difficult. If
the correlation with HLA-DRw6 is correct,
this could indicate that the formation of these
EM antibodies is under Ir gene control (man-
uscript in preparation).
Also, the distribution of the EM and other
alloantigens in kidney tissue was investigated.
Alloimmune and both polymorphic and
monomorphic monoclonal antibodies were
used. To our great surprise, we could not
demonstrate the HLA-A and Β or the HLA-
Bw4 or Bw6 or the HLA-DR antigens in a
reproducible fashion in renal tissue. The
HLA-B7 antigen is perhaps an exception. At
least some of the anti-B7 sera reacted with
vascular endothelium. Moreover monoclonal
polymorphic anti-HLA-A2 and anti-HLA-B7
antibodies were negative. In contrast, the
monomorphic monoclonal antibody against
the HLA-A, B, C molecules and against
HLA-DR molecules was strongly positive.
The HLA-LB antisera, which recognize long
or supertypic antigens on Β cells (possibly
identical or very similar to the MB1, 2, and 3
antigens described by Duquesnoy et al.),10
gave positive staining reactions in the kidney.
Α monoclonal anti-MBl antibody, however,
was only doubtfully positive.
The ABO antigens are present on the endo-
thelium of arteries, arterioles, and peritubular
capillaries." These findings raise more ques-
tions than they answer. In the first place, how
can we find a correlation between matching
for HLA-A and Β and HLA-DR if these
antigens are not present in kidney tissue? Of
course one can argue that the test was not
sensitive enough for the detection of these
antigens. The fact that more potent mono-
clonal monomorphic antibodies were positive
could be in agreement with such an assump-
tion.
The finding that the LB or MB antigens
could be easily demonstrated on kidney tissue
seems to lend support to the findings of
Duquesnoy et al. that matching for these
antigens improves graft survival.'2 We have so
far not been able to substantiate their data,
but further studies in this direction are
certainly warranted. All this emphasizes the
important role EM antigens might have as
targets in graft rejection.
Finally, we want to discuss the evidence for
a role of host factors in graft survival. Wilson
and Kirkpatrick studied a group of patients
with skin tests for microbial antigens and
could show that those patients who had posi-
tive skin tests had first rejection crises which
were on the average, on day 4, and thus a lot
earlier than those who had negative skin tests
(first rejection on day 14)." Α few years later,
Ceppellini studied the difference in graft
survival if one donor gives a skin graft to two
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recipients with the difference in graft survival
if two donors give a skin graft torone recipient.
It turns out that in the first case, the differ-
ence in graft survival is significantly greater.
All these grafts were obtained from unrelated
donors and were HLA-mismatched. This can
be interpreted as an argument for the exis-
tance of host factors and their relevance for
graft survival.14 More recently, Diamondop-
oulos et al. performed skin tests with DNCB
in a quantitative manner. Seventy percent of
grafts with a DNCB score of less than 3 were
still functioning after 6 months, while those
that had a DNCB score of greater than 3 had
a graft survival of 11% only.15
Our group and others16 l8 have approached
the problem by using the cell-mediated
lympholysis (CML) test. We consider the
CML test as the best in vitro equivalent of the
homograft reaction. Lymphocytes from the
spieen of the kidney donor were frozen in
liquid nitrogen. This was also done with
lymphocytes from the kidney recipient at
several intervals before blood transfusion,
after blood transfusion, and before transplan-
tation and after transplantation. The samples
of one patient were tested all on the same day
against the splenocytes of his specific kidney
donor.
Goulmy studied 55 patients and found that
about two-thirds of them became CML-
nonresponsive to the specific kidney donor.
This CML nonreäctivity is donor-specific
because the lymphocytes of the recipient,
when tested against the lymphocytes of an
unrelated donor in the CML test, gave a
positive reaction. It turned out that CML
nonreäctivity coincides in a significant man-
ner with good renal function. What we are
studying is thus also clinically relevant.
Recipients of male to male grafts and those
that were HLA-B compatible had the best
chance to become CML nonreactive against
their donor. It was further of interest that
recipients who were DR4-positive appear to
be especially prone to develop CML nonreäc-
tivity. This might be an indication that the
occurrence of CML nonreäctivity is also
under Ir gene control. It is clear that these
data must be considered as preliminary and
further studies are needed.20
In summary, we think that the most impor-
tant factor in the determination of graft
survival might be the responsiveness of the
graft recipient (Table 1). If the recipient is a
low responder, neither matching for DR,
blood transfusion, or matching for the
HLA-A or Β or EM antigens is necessary.
However, if the recipient is a responder, these
factors become important. If a blood transfu-
sion is given, the recognition phase initiated
through differences for the HLA-DR anti-
gens between donor and recipient can be
blocked. Matching for HLA-DR is then not
of such great importance and matching for
the HLA-A and Β and EM antigens is not
necessary either. If no blood transfusion is
given, or the blood transfusions were ineffec-
tive, then matching for DR can still block the
recognition phase and matching for HLA-A
and Β is not (or less) necessary. If no blood
transfusion is given and the kidney is DR
mismatched, matching for the HLA-A and Β
antigens and possibly the EM antigens could
still predispose for good kidney graft survival.
However, if no blood transfusions are given or
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the blood transfusion has not been effective in
blocking the effect of an HLA-DR mismatch
and donor and recipient are mismatched for
the HLA-A and Β and EM antigens as well,
graft failure will ensue in most instances. Of
course this IS only a schematic summary of
what we have discussed and must be regarded
as a working hypothesis. However, it is
certain that many factors influence graft
survival and that there are many different
levels that determine whether the graft will be
successful or will be rejected.
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